FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897581755> ?p ?o ?g. }

• W2897581755 endingPage "viii321" @default.
• W2897581755 startingPage "viii320" @default.
• W2897581755 abstract "Background: Well-defined prognostic factors (PF) and risk groups have been shown to impact OS in first- and second-line chemotherapy (chemo) for UC. Post hoc analysis of survival outcome per level of risk was conducted using data from the phase 3 KEYNOTE-045 trial (NCT02256436). Methods: Data from the Oct 26, 2017 data cut were included. The presence or absence of 4 predefined criteria applied at study randomization was noted for each patient: ECOG PS (0 vs 1 or 2), hemoglobin level (<10 g/dL vs ≥ 10 g/dL), liver metastases (yes vs no), and time from prior chemotherapy (<3 months vs ≥ 3 months). Patients were grouped per the number of PFs they had (0, 1, 2, or 3/4), and OS was estimated for each risk group receiving pembrolizumab (pembro) or chemo, using Kaplan-Meier (K-M) statistics. Results: Data from 529/542 patients were included. Stratified randomization ensured that the distribution of risk levels was similar between the 2 treatment arms. Overall, OS decreased with increasing numbers of PFs for pembro (from 19 to 5 months) and chemo (from 18 to 3 months) (Table). Within the chemo arm, the results of the K-M survival profiles were consistent with previously published data, in which each risk group had different outcomes. Within the pembro arm, outcomes of pts with 0 and 1 PF were distinct from those with 2 and 3/4 PF groups. OS was longer with pembro than with chemo across all PF subgroups. Conclusions: OS within the pembro and chemo arms decreased with increasing numbers of PFs. OS of patients treated with pembro was longer than those receiving chemo across the risk groups. Patients treated with pembro who had 2 or 3/4 PFs had overall similar outcomes. Additional analyses are needed to characterize novel risk models for patients treated with immunotherapies.Table: 901P0 PFS1 PF2 PFs3 or 4 PFsOSPembro n = 54Chemo n = 45Pembro n = 97Chemo n = 97Pembro n = 66Chemo n = 80Pembro n = 45Chemo n = 45Median (95% CI),months18.5 (14.1-NE)17.6 (10.2-24.2)12.6 (8.1-18.9)8.8 (7.4-11.2)5.1 (2.8-8.7)4.7 (3.5-6.1)4.6 (2.3-7.4)3.4 (2.4-4.6)24-month OS, %41.436.735.317.812.65.613.7NR30-month OS, %41.431.625.913.7NR5.611.4NRHR for OS0.81 (0.49-1.36)0.67 (0.48-0.93)0.82 (0.57-1.16)0.61 (0.39-0.97) Open table in a new tab Clinical trial identification: NCT02256436, trial initiation date: October 3, 2014. Editorial acknowledgement: Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck & Co., Inc., Kenilworth, NJ, USA. Legal entity responsible for the study: Merck & Co., Inc. Funding: Merck & Co., Inc. Disclosure: J. Bellmunt: Consultant/advisory: Pierre Fabre, Astellas, Pfizer, Merck, Genentech, Novartis, AstraZeneca, BMS; Travel: Pfizer, MSD Oncology; Research funding: Millennium, Sanofi. R. de Wit: Consultant/advisory: Sanofi, Merck, Lilly, Roche/Genentech; Honoraria: Sanofi, Lilly, Roche/Genentech, Merck; Research funding: Sanofi. D.J. Vaughn: Research funding: Merck, Roche, Genentech. Y. Fradet: Consultant/Advisory: Merck, Astellas, Roche, AstraZeneca; Research funding: Astellas; Travel: Roche. J.L. Lee: Consultant/Advisory: Astellas, AstraZeneca, Eisai; Honoraria: Pfizer, Astellas, Novartis, BMS; Research funding: Pfizer, Janssen, Novartis, Exelixis, BMS, Roche/Genentech. L. Fong: Consultant/Advisory: Atreca, Ideava Biosciences, MIODx; Research funding: BMS, Abbvie, Roche/Genentech, Janssen, Merck, Nektar. N.J. Vogelzang: Consultant/Advisory: Amgen, Pfizer, Bayer, Genentech/Roche, AstraZeneca, Caris Life Science, Tolero; Speakers’ bureau: Bayer, Sanofi, BMS, Exelixis, AstraZeneca, Stock, Caris Life Sciences, Honoraria: Pfizer; Research funding: Endocyte, Merck. M.A. Climent: Honoraria: Roche, BMC, Bayer, Astella, Sanofi, Pfizer, Novartis; Consulting/Advisory: Janssen, Pfizer, Roche, Sanofi, Astellas Pharma, Bayer; Travel: Astellas, Janssen, Pfizer. D. Petrylak: Consultant/Advisory: Bayer, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche, Sanofi; Research funding: Johnson & Johnson, Sanofi, Endocyte, Genentech, Merck, Astellas, Novartis, AstraZeneca, Bayer, Lilly, Seattle Genetics. T.K. Choueiri: Consultant: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, BMS Roche/Genentech, Eisai, AstraZeneca, Exelixis, Alligent; Honoraria: NCCN; Research funding: Pfizer, Novartis, Merck, Exelixis, GlaxoSmithKline, BMS, AstraZeneca, Roche/Genentech, Celldex. W.R. Gerritsen: Consultant/Advisory: BMS, Amgen, Merck, Aglaia Biomedical Ventures, Astellas, Bayer, Janssen-Cilag; Speakers’ bureau: Astellas, Bayer, Janssen-Cilag; Travel: Amgen, Bayer. H. Gurney: Consultant/Advisory: BMS, Ipsen, Merck, AstaZeneca; Travel: Astellas, Sanofi; Honoraria: Roche, Astellas; Research funding: Pfizer. D.I. Quinn: Consultant/Advisory: Astellas, Pfizer, BMS, Genetech/Roche, Merck, Bayer, Exelixis, AstraZeneca, Sanofi; Honoraria: Bayer, Astellas, Pfizer, Genentech/Roche, Merck, BMS, AstraZeneca, Sanofi, Millennium, Genentech/Roche, GlaxoSmithKline. S. Culine: Consultant/Advisory: Roche, Janssen; Speakers bureau: Astellas, Roche, Merck; Travel: Amgen, Astellas, Janssen. C.N. Sternberg: Honararia: OncoGenex, Lilly, Janssen, Merck, BMS, AstraZeneca, Roche/Genentech; Research funding: Lilly, Janssen, Merck, BMS, AstraZeneca, Roche/Genentech. E. Jensen: Employment: Merck. T. Frenkl, R.F. Perini: Employment and stock. D. Bajorin: BMS, Novartis, Roche/Genentech, Merck, Lilly, Fidia Farmaceutici, Urogen Pharma, Lilly Pfizer, EMD Serono; Honoraria: Merck; Research funding: Dendreon, Novartis, Amgen. Genentech/Roche, Merck, BMS. All other authors have declared no conflicts of interest." @default.
• W2897581755 created "2018-10-26" @default.
• W2897581755 creator A5002821481 @default.
• W2897581755 creator A5004167433 @default.
• W2897581755 creator A5004985848 @default.
• W2897581755 creator A5031088617 @default.
• W2897581755 creator A5035439869 @default.
• W2897581755 creator A5039709555 @default.
• W2897581755 creator A5041526616 @default.
• W2897581755 creator A5041610986 @default.
• W2897581755 creator A5044337611 @default.
• W2897581755 creator A5048126701 @default.
• W2897581755 creator A5050042851 @default.
• W2897581755 creator A5052504518 @default.
• W2897581755 creator A5059219836 @default.
• W2897581755 creator A5064884168 @default.
• W2897581755 creator A5068785092 @default.
• W2897581755 creator A5071441111 @default.
• W2897581755 creator A5073970384 @default.
• W2897581755 creator A5074756323 @default.
• W2897581755 creator A5075327765 @default.
• W2897581755 creator A5083331837 @default.
• W2897581755 date "2018-10-01" @default.
• W2897581755 modified "2023-10-18" @default.
• W2897581755 title "Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045" @default.
• W2897581755 doi "https://doi.org/10.1093/annonc/mdy283.110" @default.
• W2897581755 hasPublicationYear "2018" @default.
• W2897581755 type Work @default.
• W2897581755 sameAs 2897581755 @default.
• W2897581755 citedByCount "2" @default.
• W2897581755 countsByYear W28975817552023 @default.
• W2897581755 crossrefType "journal-article" @default.
• W2897581755 hasAuthorship W2897581755A5002821481 @default.
• W2897581755 hasAuthorship W2897581755A5004167433 @default.
• W2897581755 hasAuthorship W2897581755A5004985848 @default.
• W2897581755 hasAuthorship W2897581755A5031088617 @default.
• W2897581755 hasAuthorship W2897581755A5035439869 @default.
• W2897581755 hasAuthorship W2897581755A5039709555 @default.
• W2897581755 hasAuthorship W2897581755A5041526616 @default.
• W2897581755 hasAuthorship W2897581755A5041610986 @default.
• W2897581755 hasAuthorship W2897581755A5044337611 @default.
• W2897581755 hasAuthorship W2897581755A5048126701 @default.
• W2897581755 hasAuthorship W2897581755A5050042851 @default.
• W2897581755 hasAuthorship W2897581755A5052504518 @default.
• W2897581755 hasAuthorship W2897581755A5059219836 @default.
• W2897581755 hasAuthorship W2897581755A5064884168 @default.
• W2897581755 hasAuthorship W2897581755A5068785092 @default.
• W2897581755 hasAuthorship W2897581755A5071441111 @default.
• W2897581755 hasAuthorship W2897581755A5073970384 @default.
• W2897581755 hasAuthorship W2897581755A5074756323 @default.
• W2897581755 hasAuthorship W2897581755A5075327765 @default.
• W2897581755 hasAuthorship W2897581755A5083331837 @default.
• W2897581755 hasBestOaLocation W28975817551 @default.
• W2897581755 hasConcept C121608353 @default.
• W2897581755 hasConcept C126322002 @default.
• W2897581755 hasConcept C143998085 @default.
• W2897581755 hasConcept C204243189 @default.
• W2897581755 hasConcept C2776694085 @default.
• W2897581755 hasConcept C2777701055 @default.
• W2897581755 hasConcept C2780057760 @default.
• W2897581755 hasConcept C2780258809 @default.
• W2897581755 hasConcept C2780352672 @default.
• W2897581755 hasConcept C3019894029 @default.
• W2897581755 hasConcept C3020745361 @default.
• W2897581755 hasConcept C535046627 @default.
• W2897581755 hasConcept C67761136 @default.
• W2897581755 hasConcept C71924100 @default.
• W2897581755 hasConceptScore W2897581755C121608353 @default.
• W2897581755 hasConceptScore W2897581755C126322002 @default.
• W2897581755 hasConceptScore W2897581755C143998085 @default.
• W2897581755 hasConceptScore W2897581755C204243189 @default.
• W2897581755 hasConceptScore W2897581755C2776694085 @default.
• W2897581755 hasConceptScore W2897581755C2777701055 @default.
• W2897581755 hasConceptScore W2897581755C2780057760 @default.
• W2897581755 hasConceptScore W2897581755C2780258809 @default.
• W2897581755 hasConceptScore W2897581755C2780352672 @default.
• W2897581755 hasConceptScore W2897581755C3019894029 @default.
• W2897581755 hasConceptScore W2897581755C3020745361 @default.
• W2897581755 hasConceptScore W2897581755C535046627 @default.
• W2897581755 hasConceptScore W2897581755C67761136 @default.
• W2897581755 hasConceptScore W2897581755C71924100 @default.
• W2897581755 hasLocation W28975817551 @default.
• W2897581755 hasOpenAccess W2897581755 @default.
• W2897581755 hasPrimaryLocation W28975817551 @default.
• W2897581755 hasRelatedWork W2585407512 @default.
• W2897581755 hasRelatedWork W2794371418 @default.
• W2897581755 hasRelatedWork W2891524425 @default.
• W2897581755 hasRelatedWork W2950551738 @default.
• W2897581755 hasRelatedWork W2981222449 @default.
• W2897581755 hasRelatedWork W3037068108 @default.
• W2897581755 hasRelatedWork W3041652591 @default.
• W2897581755 hasRelatedWork W3089276285 @default.
• W2897581755 hasRelatedWork W4200023723 @default.
• W2897581755 hasRelatedWork W4248584487 @default.
• W2897581755 hasVolume "29" @default.
• W2897581755 isParatext "false" @default.
• W2897581755 isRetracted "false" @default.
• W2897581755 magId "2897581755" @default.

• next